L. Schechter

发表

Neuropharmacological Profile of Novel and Selective 5-HT6 Receptor Agonists: WAY-181187 and WAY-208466

Derek Cole, Qin Shan, A. Robichaud, 2008, Neuropsychopharmacology.

Identification of a human 5-HT6 receptor variant produced by alternative splicing.

S. Nawoschik, L. Schechter, M. Burno, 1999, Brain research. Molecular brain research.

The C-terminus of Gi family G-proteins as a determinant of 5-HT(1A) receptor coupling.

Q. Shan, S. Nawoschik, J. Dunlop, 2002, Biochemical and biophysical research communications.

Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods to study brain neurochemistry

C. Beyer, P. Mcgonigle, A. Bach, 2004, Journal of Neuroscience Methods.

Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression

P. Rada, L. Schechter, L. Hernández, 2010, Pharmacology Biochemistry and Behavior.

WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity

B. Harrison, G. Stack, S. Rosenzweig-Lipson, 2005, Journal of Pharmacology and Experimental Therapeutics.

Common pharmacological and physico-chemical properties of 5-HT3 binding sites in the rat cerebral cortex and NG 108-15 clonal cells.

M. Hamon, M. Emerit, M. Miquel, 1990, Biochemical pharmacology.

Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist

J. Barrett, B. Harrison, M. Pangalos, 2011, Journal of Pharmacology and Experimental Therapeutics.

[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.

T. Branchek, C. Gerald, R. Weinshank, 1996, European journal of pharmacology.

Ketanserin and ritanserin discriminate between recombinant human 5-HT1Dα and 5-HT1Dβ receptor subtypes

T. Branchek, J. Zgombick, R. Weinshank, 1995 .

Expression and pharmacological characterization of a canine 5-hydroxytryptamine1D receptor subtype.

T. Branchek, J. Zgombick, R. Weinshank, 1991, Molecular pharmacology.

Interaction of psychotropic drugs with central 5-HT3 recognition sites: fact or artifact?

D. Hoyer, M. Hamon, L. Schechter, 1989, European journal of pharmacology.

Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways

T. Branchek, L. Borden, R. Weinshank, 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

B. Harrison, D. Huryn, C. Beyer, 2006, Journal of medicinal chemistry.

Physicochemical Properties of Serotonin 5‐HT3 Binding Sites Solubilized from Membranes of NG 108‐15 Neuroblastoma‐Glioma Cells

M. Hamon, M. Emerit, M. Miquel, 1990, Journal of neurochemistry.

Determination of the molecular size of the 5-HT3 receptor binding site by radiation inactivation.

M. Hamon, M. Emerit, M. Miquel, 1989, European journal of pharmacology.

4-(2-Aminoethoxy)-N-(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands.

B. Harrison, A. Robichaud, D. Huryn, 2005, Bioorganic & medicinal chemistry letters.

Studies toward the discovery of the next generation of antidepressants. Part 2: incorporating a 5-HT(1A) antagonist component into a class of serotonin reuptake inhibitors.

L. Schechter, D. Smith, P. Zhou, 2002, Bioorganic & medicinal chemistry letters.

Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists.

B. Harrison, A. Robichaud, C. Beyer, 2009, Bioorganic & medicinal chemistry.

Novel benzofuran derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

B. Harrison, J. Ellingboe, L. Schechter, 2010, Bioorganic & medicinal chemistry letters.

Studies toward the discovery of the next generation of antidepressants. Part 5: 3,4-Dihydro-2H-benzo[1,4]oxazine derivatives with dual 5-HT1A receptor and serotonin transporter affinity.

B. Harrison, L. Schechter, D. Smith, 2006, Bioorganic & medicinal chemistry letters.

Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor.

Richard E Mewshaw, L. Schechter, D. Smith, 2005, Bioorganic & medicinal chemistry letters.

Novel aryloxy-8-azabicyclo[3.2.1]oct-3-enes with 5-HT transporter and 5-HT1A affinity.

T. Coleman, A. Gilbert, L. Schechter, 2004, Bioorganic & medicinal chemistry letters.

Studies Toward the Discovery of the Next Generation of Antidepressants. Part 2. Incorporating a 5‐HT1A Antagonist Component into a Class of Serotonin Reuptake Inhibitors.

L. Schechter, D. Smith, P. Zhou, 2002 .

Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors.

D. Smith, L. Schechter, P. Zhou, 2001, Bioorganic & medicinal chemistry letters.

Characterization of 5-HT1A receptor functional coupling in cells expressing the human 5-HT1A receptor as assessed with the cytosensor microphysiometer.

J. Dunlop, L. Schechter, J Dunlop, 1998, Journal of pharmacological and toxicological methods.

βSubunits Promote K+ Channel Surface Expression through Effects Early in Biosynthesis

K. Rhodes, J. Trimmer, S. Hammond, 1996, Neuron.

5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.

T. Comery, A. Robichaud, Z. Hughes, 2010, Journal of medicinal chemistry.

Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.

A. Robichaud, R. Magolda, H. Elokdah, 2007, Bioorganic & medicinal chemistry.

Identification of a series of benzoxazoles as potent 5-HT6 ligands.

T. Comery, A. Robichaud, L. Di, 2009, Bioorganic & medicinal chemistry letters.

1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-indoles as novel 5-HT6 receptor ligands.

B. Harrison, S. Antane, L. Schechter, 2004, Bioorganic & medicinal chemistry letters.

Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.

B. Harrison, C. Beyer, G. Stack, 2009, Journal of medicinal chemistry.

Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain

M. Hamon, L. Schechter, H. Gozlan, 1994, Neuropharmacology.

Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.

J. Ellingboe, G. Tawa, Guoming Zhang, 2005, Journal of medicinal chemistry.

1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI) exerts an anorexic action that is blocked by 5-HT2 antagonists in rats

L. Schechter, K. Simansky, 2004, Psychopharmacology.

Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2.

B. Harrison, Minsheng Zhang, A. Failli, 2008, Journal of medicinal chemistry.

WAY‐100635 antagonist‐induced plasticity of 5‐HT1A receptors: regulatory differences between a stable cell line and an in vivo native system

S. Nawoschik, J. Dunlop, Jean Y Zhang, 2006, Journal of neurochemistry.

Innovative approaches for the development of antidepressant drugs: Current and future strategies

C. Beyer, R. Ring, Z. Hughes, 2005, NeuroRX.

Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis study

L. Schechter, L. Dawson, H. Nguyen, 2000, British journal of pharmacology.

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

I. Lucki, D. Balu, J. Malberg, 2008, Brain Research.

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

M. Pangalos, O. Hurko, L. Schechter, 2007, Nature Reviews Drug Discovery.

CHAPTER 4 – Calmodulin Antagonists: Structure—Activity Relationships

B. Weiss, L. Schechter, J. Winkler, 1985 .

Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.

Xiaojie Shi, Richard E Mewshaw, L. Schechter, 2004, Journal of medicinal chemistry.

N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists.

J. Ellingboe, Guoming Zhang, H. Mazandarani, 2005, Bioorganic & medicinal chemistry letters.

Increasing the Levels of Insulin-Like Growth Factor-I by an IGF Binding Protein Inhibitor Produces Anxiolytic and Antidepressant-Like Effects

I. Lucki, R. Ring, J. Malberg, 2007, Neuropsychopharmacology.

Antidepressant-like behavioral effects of IGF-I produced by enhanced serotonin transmission.

I. Lucki, J. Crowley, J. Malberg, 2008, European journal of pharmacology.

Cloning, mRNA localization and evolutionary conservation of a human 5-HT7 receptor pseudogene.

L. Schechter, M. Olsen, M. Olsen, 1999, Gene.

Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives.

B. Harrison, D. Huryn, L. Schechter, 2008, Bioorganic & medicinal chemistry.

The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.

H. Kao, T. Branchek, C. Gerald, 1995, The EMBO journal.

[3H]5-methyl-urapidil labels 5-HT1A receptors and alpha 1-adrenoceptors in the rat CNS. In vitro binding and autoradiographic studies.

M. Hamon, D. Vergé, L. Schechter, 1991, European journal of pharmacology.

The main features of central 5-HT1 receptors.

L. Lanfumey, M. Hamon, S. El Mestikawy, 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes

D. Deecher, L. Schechter, D. Sloan, 2008, Psychoneuroendocrinology.

A novel approach for predicting antidepressant-induced sexual dysfunction in rats

S. J. Sukoff Rizzo, S. Rosenzweig-Lipson, L. Schechter, 2007, Psychopharmacology.

Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents.

L. Schechter, K. Simansky, 1988, The Journal of pharmacology and experimental therapeutics.

The Central 5‐HT1A Receptors: Pharmacological, Biochemical, Functional, and Regulatory Properties a

M. Hamon, M. Emerit, S. Mestikawy, 1990, Annals of the New York Academy of Sciences.

5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.

T. Comery, Radka Graf, A. Robichaud, 2010, Journal of Medicinal Chemistry.

Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.

T. Comery, A. Robichaud, L. Di, 2009, Bioorganic & medicinal chemistry letters.

Differentiating antidepressants of the future: efficacy and safety.

C. Beyer, R. Ring, Z. Hughes, 2007, Pharmacology & therapeutics.

Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.

T. Comery, A. Robichaud, L. Di, 2011, Bioorganic & medicinal chemistry.

Editorial [ Hot Topic: Antidepressant Drug Design (Executive Editor: Lee E. Schechter)]

L. Schechter, 2005 .

Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.

B. Harrison, D. Huryn, W. Childers, 2005, Journal of medicinal chemistry.

Voltage-Gated K+ Channel β Subunits: Expression and Distribution of Kvβ1 and Kvβ2 in Adult Rat Brain

K. Rhodes, J. Trimmer, N. Barrezueta, 1996, The Journal of Neuroscience.

Voltage-Gated K 1 Channel b Subunits : Expression and Distribution of Kv b 1 and Kv b 2 in Adult Rat Brain

K. Rhodes, J. Trimmer, N. Barrezueta, 1996 .

5‐HT2C and 5‐HT6 Receptor Targeted Emerging Approaches in Schizophrenia

T. Comery, K. Marquis, S. Rosenzweig-Lipson, 2012 .

Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders

C. Beyer, J. Dwyer, R. Ring, 2008, Psychopharmacology.

Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats

I. Lucki, L. Schechter, Gregory V. Carr, 2011, Psychopharmacology.

3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators.

B. Harrison, A. Robichaud, S. Antane, 2010, Bioorganic & medicinal chemistry letters.

1-(2-Aminoethyl)-3-(arylsulfonyl)-1H-pyrrolopyridines are 5-HT(6) receptor ligands.

B. Harrison, A. Robichaud, S. Antane, 2009, Bioorganic & medicinal chemistry letters.

Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405)

M. Day, T. Comery, S. Grauer, 2008, Journal of Pharmacology and Experimental Therapeutics.

Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation

C. Beyer, J. Dwyer, S. Rosenzweig-Lipson, 2010, Psychopharmacology.

Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine

C. Beyer, R. Ring, S. Rosenzweig-Lipson, 2008, Brain Research.

Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications

R. Ring, J. Malberg, S. Rosenzweig-Lipson, 2006, Psychopharmacology.

5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats.

Z. Hughes, G. Stack, S. J. Sukoff Rizzo, 2009, The international journal of neuropsychopharmacology.

Acute and chronic administration of the selective 5‐HT1A receptor antagonist WAY‐405 significantly alters the activity of midbrain dopamine neurons in rats: An in vivo electrophysiological study

K. Hashimoto, Y. Minabe, C. Ashby, 1999, Synapse.

Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies.

S. Haj-Dahmane, L. Lanfumey, M. Hamon, 1990, The Journal of pharmacology and experimental therapeutics.

Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs.

J. Malberg, L. Schechter, 2005, Current pharmaceutical design.

Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist.

K. Marquis, C. Beyer, J. Ellingboe, 2007, Journal of medicinal chemistry.

Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon

C. Beyer, R. Ring, S. Rosenzweig-Lipson, 2007, Neuropeptides.

Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse.

I. Lucki, J. Dwyer, D. Balu, 2009, Journal of pharmacological and toxicological methods.

Lecozotan (SRA-333): A Selective Serotonin 1A Receptor Antagonist That Enhances the Stimulated Release of Glutamate and Acetylcholine in the Hippocampus and Possesses Cognitive-Enhancing Properties

J. Barrett, K. Marquis, J. Buccafusco, 2005, Journal of Pharmacology and Experimental Therapeutics.

The potassium channel blockers 4-aminopyridine and tetraethylammonium increase the spontaneous basal release of [3H]5-hydroxytryptamine in rat hippocampal slices.

L. Schechter, 1997, The Journal of pharmacology and experimental therapeutics.

Regulators of G-protein signaling 4: modulation of 5-HT1A-mediated neurotransmitter release in vivo

K. Rhodes, C. Beyer, Afshin Ghavami, 2004, Brain Research.

The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease.

L. Schechter, L. Dawson, J. Harder, 2002, Current pharmaceutical design.

WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent

F. Liu, M. Day, J. Dwyer, 2008, Neuropharmacology.

1-Sulfonylindazoles as potent and selective 5-HT6 ligands.

Li Di, Edward H Kerns, Guo Ming Zhang, 2009, Bioorganic & medicinal chemistry letters.

Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex

L. Schechter, L. Dawson, H. Nguyen, 2002, Journal of psychopharmacology.

Serotonin receptor subtypes.

H. Kao, T. Branchek, J. Zgombick, 1993, Psychopharmacology series.

A Positron Emission Tomography Study to Assess Binding of Lecozotan, a Novel 5‐Hydroxytryptamine‐1A Silent Antagonist, to Brain 5‐HT1A Receptors in Healthy Young and Elderly Subjects, and in Patients With Alzheimer's Disease

B. Långstrom, A. Patat, J. Paul, 2008, Clinical pharmacology and therapeutics.

Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist

K. Marquis, S. Grauer, Radka Graf, 2010, Neuropharmacology.

Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism.

L. Leventhal, C. Beyer, J. Dwyer, 2010, The international journal of neuropsychopharmacology.

Novel pyridyl-fused 3-amino chroman derivatives with dual action at serotonin transporter and 5-HT1A receptor.

B. Harrison, G. Stack, L. Schechter, 2007, Bioorganic & medicinal chemistry letters.

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression

J. Brennan, J. Dwyer, R. Ring, 2013, Neuropharmacology.

Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor.

T. Branchek, J. Zgombick, R. Weinshank, 1992, Molecular pharmacology.

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.

Preclinical characterization of WAY‐211612: a dual 5‐HT uptake inhibitor and 5‐HT1A receptor antagonist and potential novel antidepressant

R. Magolda, J. Malberg, S. Rosenzweig-Lipson, 2009, British journal of pharmacology.

Pharmacological characterizations of recombinant human 5-HT1D1Dα and 5-HT1Dβ receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes

T. Branchek, J. Zgombick, R. Weinshank, 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach.

Purnima Khandelwal, C. Beyer, A. Bach, 2004, Analytical chemistry.

The effects of systemic and local microinjection into the central nervous system of the selective serotonin 5-HT6 receptor agonist WAY-208466 on sleep and wakefulness in the rat

J. Monti, H. Jantos, L. Schechter, 2013, Behavioural Brain Research.

Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.

H. Kao, T. Branchek, R. Weinshank, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.

J. Ellingboe, G. Tawa, Guoming Zhang, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporter.

B. Harrison, W. Childers, Zhongqi Shen, 2010, Bioorganic & medicinal chemistry letters.

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

I. Lucki, D. Balu, J. Malberg, 2008, Brain Research.

A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands.

T. Comery, A. Robichaud, L. Di, 2008, Bioorganic & medicinal chemistry letters.

Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein.

S. Nawoschik, J. Dunlop, Jean Y Zhang, 2003, European journal of pharmacology.

Voltage-gated K+ channel beta subunits: expression and distribution of Kv beta 1 and Kv beta 2 in adult rat brain.

K. Rhodes, J. Trimmer, N. Barrezueta, 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine.

C. Beyer, S. Rosenzweig-Lipson, L. Schechter, 2006, European journal of pharmacology.

Concomitant blockade of 5-HT1A receptor and 5-HT transporter: Use of the Hunter Serotonin Toxicity Criteria in a clinical pharmacology study

A. Płotka, S. Chalon, L. Schechter, 2008, European Neuropsychopharmacology.